Pharmacologic Treatment for PTSD in Adults
For adults with PTSD, start with an SSRI (sertraline or paroxetine) or the SNRI venlafaxine as first-line pharmacotherapy, based on the strongest guideline evidence. 1
First-Line Pharmacotherapy
The 2024 VA/DoD Clinical Practice Guideline provides the most authoritative recommendation: SSRIs (specifically paroxetine and sertraline) or venlafaxine are the recommended first-line medications for PTSD 1. This represents a strong recommendation based on systematic evidence review using GRADE methodology.
Evidence Supporting SSRIs
- SSRIs demonstrate moderate-certainty evidence for treatment response, with 58% of SSRI-treated patients improving compared to 35% on placebo (RR 0.66,95% CI 0.59-0.74) 2
- Among individual agents, fluoxetine, paroxetine, and venlafaxine show small but statistically significant efficacy 3
- The effect size is modest (SMD -0.23), but clinically meaningful for many patients 3
Practical Considerations
Dropout rates are slightly higher with SSRIs (9% vs placebo), particularly with paroxetine (RR 1.55), though absolute rates remain low 2. This is based on moderate-certainty evidence and should inform patient counseling about tolerability.
Second-Line Options
When SSRIs/SNRIs are ineffective or not tolerated:
Mirtazapine (NaSSA)
- Shows beneficial effect with 65% response rate vs 22% placebo (RR 0.45) 2
- Low-certainty evidence but may be considered when first-line agents fail
- Ranks relatively high for efficacy in network meta-analyses 4
Tricyclic Antidepressants
- Amitriptyline demonstrated 50% response vs 17% placebo (RR 0.60) 2
- Based on low-certainty evidence from limited trials
- Consider when other options exhausted, accounting for TCA side effect profile
Medications NOT Recommended
The VA/DoD guideline makes strong recommendations AGAINST:
- Benzodiazepines - explicitly not recommended 1
- Cannabis or cannabis-derived products - strong recommendation against use 1
Augmentation Strategies
Atypical Antipsychotics
For treatment-resistant PTSD or when psychotic symptoms present:
- Aripiprazole, risperidone, or olanzapine may be used for augmentation 5
- Evidence quality is lower; these are not first-line monotherapy
- The 2018 AASM position paper lists these as "may be used" for PTSD-associated symptoms 5
Other Augmentation Agents
The following "may be used" based on limited evidence 5:
- Gabapentin
- Topiramate
- Trazodone
- Clonidine
- Cyproheptadine
Special Consideration: PTSD-Related Nightmares
For prominent nightmare symptoms, prazosin remains an option despite recent evidence downgrades 5. The 2018 AASM guidelines note prazosin "may be used" for PTSD-associated nightmares, though confidence has decreased based on more recent negative trials 5.
- Start at 1 mg at bedtime, titrate by 1-2 mg every few days
- Effective doses range 1-15 mg (average 3-9 mg)
- Monitor for orthostatic hypotension
- Note: Efficacy may be reduced in patients taking SSRIs concurrently 5
Critical Pitfalls to Avoid
- Do not use clonazepam or venlafaxine specifically for nightmare disorder - these are explicitly not recommended 5
- Avoid benzodiazepines entirely - strong evidence against use in PTSD 1
- Do not prescribe cannabis products - no evidence of benefit and potential harm 1
- Antipsychotics as monotherapy lack evidence - very low-certainty evidence for efficacy (RR 0.51,95% CI 0.16-1.67) 2
Treatment Algorithm
- Initiate SSRI (sertraline or paroxetine) or venlafaxine
- Adequate trial: 8-12 weeks at therapeutic dose
- If partial response: Optimize dose, continue 6+ months
- If inadequate response: Switch to alternative SSRI/SNRI
- If still inadequate: Consider mirtazapine or augmentation with atypical antipsychotic
- For prominent nightmares: Add prazosin (monitor BP)
- Throughout: Combine with trauma-focused psychotherapy when available (psychotherapy is preferred over medication alone per VA/DoD guidelines) 1
Evidence Quality Context
The pharmacotherapy evidence base for PTSD remains moderate at best, with most medications showing small effect sizes 2, 3. The 2022 Cochrane review emphasizes that important gaps remain in the evidence base, with continued need for more effective agents 2. Network meta-analyses suggest phenelzine may have superior efficacy, but insufficient data prevents strong recommendations 4.
Psychotherapy (particularly trauma-focused CBT, prolonged exposure, cognitive processing therapy, or EMDR) is strongly preferred over pharmacotherapy alone when available 1, though medication remains an important option when psychotherapy is unavailable, refused, or insufficient.